Treatment of elderly patients affected by lung cancer: Why to treat, when to treat and what we know

Alessandra Bearz; Massimiliano Berretta; Arben Lleshi; Eleonora Berto; Umberto Tirelli

doi:10.2174/18715206113136660353

Treatment of elderly patients affected by lung cancer: Why to treat, when to treat and what we know

Alessandra Bearz, Massimiliano Berretta, Arben Lleshi, Eleonora Berto, Umberto Tirelli

Centro di Riferimento Oncologico

Research output: Contribution to journal › Article › peer-review

Abstract

In the recent years many advances have been achieved in the field of the treatment of lung cancer, with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.

Original language	English
Pages (from-to)	1378-1382
Number of pages	5
Journal	Anti-Cancer Agents in Medicinal Chemistry
Volume	13
Issue number	9
DOIs	https://doi.org/10.2174/18715206113136660353
Publication status	Published - 2013

Keywords

Adjuvant treatment
Chemotherapy
Clinical trials
Comprehensive geriatric assessment
Cutoff point
Elderly patients
Geriatric oncology
Locally advanced nsclc
Lung cancer
Metastatic lung cancer
Multimodality treatment
Non-small cell lung cancer
Radiotherapy
Small cell lung cancer
Surgery

ASJC Scopus subject areas

Cancer Research
Molecular Medicine
Pharmacology
Medicine(all)

Access to Document

10.2174/18715206113136660353

Cite this

@article{9d0b23008282475e9f7dc5b98fe689a5,

title = "Treatment of elderly patients affected by lung cancer: Why to treat, when to treat and what we know",

abstract = "In the recent years many advances have been achieved in the field of the treatment of lung cancer, with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.",

keywords = "Adjuvant treatment, Chemotherapy, Clinical trials, Comprehensive geriatric assessment, Cutoff point, Elderly patients, Geriatric oncology, Locally advanced nsclc, Lung cancer, Metastatic lung cancer, Multimodality treatment, Non-small cell lung cancer, Radiotherapy, Small cell lung cancer, Surgery",

author = "Alessandra Bearz and Massimiliano Berretta and Arben Lleshi and Eleonora Berto and Umberto Tirelli",

year = "2013",

doi = "10.2174/18715206113136660353",

language = "English",

volume = "13",

pages = "1378--1382",

journal = "Anti-Cancer Agents in Medicinal Chemistry",

issn = "1871-5206",

publisher = "Bentham Science Publishers B.V.",

number = "9",

}

TY - JOUR

T1 - Treatment of elderly patients affected by lung cancer

T2 - Why to treat, when to treat and what we know

AU - Bearz, Alessandra

AU - Berretta, Massimiliano

AU - Lleshi, Arben

AU - Berto, Eleonora

AU - Tirelli, Umberto

PY - 2013

Y1 - 2013

N2 - In the recent years many advances have been achieved in the field of the treatment of lung cancer, with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.

AB - In the recent years many advances have been achieved in the field of the treatment of lung cancer, with the development of novel therapeutic pathways due to the knowledge of oncologic drivers involved in the carcinogenesis of the lung, as well as the involvement of new radiotherapic and surgical techniques. Nevertheless, the standard treatment for elderly is still debated, mainly because of an underrepresentation of elderly patients in clinical trials. Herein we try to summarize the main guidelines for the treatment of lung cancer, with particular attention for the elderly patients, what we know and what has changed.

KW - Adjuvant treatment

KW - Chemotherapy

KW - Clinical trials

KW - Comprehensive geriatric assessment

KW - Cutoff point

KW - Elderly patients

KW - Geriatric oncology

KW - Locally advanced nsclc

KW - Lung cancer

KW - Metastatic lung cancer

KW - Multimodality treatment

KW - Non-small cell lung cancer

KW - Radiotherapy

KW - Small cell lung cancer

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84888258719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888258719&partnerID=8YFLogxK

U2 - 10.2174/18715206113136660353

DO - 10.2174/18715206113136660353

M3 - Article

C2 - 24102274

AN - SCOPUS:84888258719

SN - 1871-5206

VL - 13

SP - 1378

EP - 1382

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

IS - 9

ER -

Treatment of elderly patients affected by lung cancer: Why to treat, when to treat and what we know

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this